PRAKASH MASAND to Delayed-Action Preparations
This is a "connection" page, showing publications PRAKASH MASAND has written about Delayed-Action Preparations.
Connection Strength
0.295
-
A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics. 2009 Jan-Feb; 50(1):78-86.
Score: 0.078
-
Long-acting injectable antipsychotics in the elderly: guidelines for effective use. Drugs Aging. 2003; 20(15):1099-110.
Score: 0.051
-
Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison. Int Clin Psychopharmacol. 2017 09; 32(5):235-248.
Score: 0.035
-
History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 31; 33(6):996-1002.
Score: 0.020
-
Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. J Clin Pharm Ther. 2009 Feb; 34(1):79-88.
Score: 0.020
-
History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. World J Biol Psychiatry. 2009; 10(4 Pt 2):435-41.
Score: 0.019
-
Paroxetine: safety and tolerability issues. Expert Opin Drug Saf. 2008 Nov; 7(6):783-94.
Score: 0.019
-
Long-acting injectable naltrexone for the treatment of alcohol dependence. Expert Rev Neurother. 2007 Oct; 7(10):1265-77.
Score: 0.018
-
A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med. 2007 May; 120(5):448-54.
Score: 0.017
-
A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol. 2006 Dec; 26(6):653-6.
Score: 0.017